Jianerkang Medical Co.,Ltd. (SHA:603205)
China · Delayed Price · Currency is CNY 21.08
0.00 (0.00%)
At close: Aug 4, 2026
Jianerkang Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,288 | 4,460 | 4,594 | - | - | - | |
Market Cap Growth | -29.94% | -2.91% | - | - | - | - |
Enterprise Value | 2,535 | 3,745 | 4,284 | - | - | - |
Last Close Price | 21.08 | 28.25 | 28.84 | - | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 29.70 | 40.02 | 38.21 | - | - | - |
PS Ratio | 3.22 | 4.35 | 4.39 | - | - | - |
PB Ratio | 2.16 | 2.98 | 3.24 | - | - | - |
P/TBV Ratio | 2.24 | 3.10 | 3.37 | - | - | - |
P/FCF Ratio | 43.91 | 50.22 | 45.32 | - | - | - |
P/OCF Ratio | 22.23 | 28.09 | 32.56 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.48 | 3.66 | 4.10 | - | - | - |
EV/EBITDA Ratio | 14.84 | 23.02 | 26.24 | - | - | - |
EV/EBIT Ratio | 20.66 | 31.67 | 35.51 | - | - | - |
EV/FCF Ratio | 33.85 | 42.18 | 42.27 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.02 | - | - | 0.04 | 0.08 |
Debt / EBITDA Ratio | 0.11 | 0.13 | - | - | 0.17 | 0.38 |
Debt / FCF Ratio | 0.25 | 0.25 | - | - | 0.31 | 2.28 |
Net Debt / Equity Ratio | -0.49 | -0.50 | -0.51 | -0.25 | -0.19 | -0.08 |
Net Debt / EBITDA Ratio | -4.49 | -4.57 | -4.42 | -1.35 | -0.83 | -0.36 |
Net Debt / FCF Ratio | -10.06 | -8.37 | -7.12 | -3.07 | -1.53 | -2.17 |
Asset Turnover | 0.62 | 0.62 | 0.77 | 0.97 | 1.17 | 0.94 |
Inventory Turnover | 4.39 | 4.55 | 4.85 | 4.88 | 5.07 | 3.64 |
Quick Ratio | 7.61 | 6.18 | 7.04 | 2.84 | 1.83 | 1.39 |
Current Ratio | 9.16 | 7.24 | 8.43 | 3.87 | 2.82 | 2.34 |
Return on Equity (ROE) | 7.41% | 7.65% | 10.32% | 14.60% | 22.47% | 24.07% |
Return on Assets (ROA) | 4.65% | 4.48% | 5.58% | 7.36% | 9.52% | 7.59% |
Return on Invested Capital (ROIC) | 14.23% | 14.38% | 15.25% | 16.58% | 20.92% | 17.40% |
Return on Capital Employed (ROCE) | 7.80% | 7.70% | 8.30% | 13.30% | 17.20% | 15.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.35% | 2.50% | 2.62% | - | - | - |
FCF Yield | 2.28% | 1.99% | 2.21% | - | - | - |
Dividend Yield | 1.19% | 0.89% | 1.22% | - | - | - |
Payout Ratio | 38.25% | 37.80% | - | 0.56% | 1.06% | 1.60% |
Buyback Yield / Dilution | -14.91% | -26.64% | -5.71% | -0.21% | 0.01% | -12.43% |
Total Shareholder Return | -13.70% | -25.75% | -4.50% | -0.21% | 0.01% | -12.43% |